Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Thread Embedding Acupuncture Added to Antihistamine Treatment for Chronic Urticaria

12 november 2026 uppdaterad av: Do Thanh Sang, University of Medicine and Pharmacy at Ho Chi Minh City

Evaluation of the Efficacy and Safety of Thread Embedding Acupuncture Combined With an H1 Antihistamine for the Treatment of Chronic Urticaria

This study will test whether adding thread embedding acupuncture to an antihistamine helps adults with chronic hives whose symptoms remain bothersome despite taking the antihistamine. In thread embedding acupuncture, a clinician uses a needle to place a small dissolvable thread at an acupuncture point. The comparison procedure uses the same acupuncture points and a needle, without placing a thread. Both groups take cetirizine.

The researchers plan to enroll 124 adults at three hospitals in Ho Chi Minh City, Vietnam. Participants will be assigned by chance to one of the two groups. They will receive two procedures, two weeks apart. Participants and the people who assess their symptoms will not know which procedure they received. The main assessment compares changes in hives and itching after four weeks. The study will also assess quality of life, a blood marker called total immunoglobulin E, additional antihistamine use, side effects, and whether symptoms return during follow-up through week 8.

Studieöversikt

Detaljerad beskrivning

This multicenter, randomized, sham-controlled, parallel-group trial compares polydioxanone (PDO) thread embedding acupuncture plus cetirizine with sham thread embedding acupuncture plus cetirizine. Eligible adults will complete a 7-day run-in with oral cetirizine 10 mg daily and a daily hives and itch diary. Participants with a 7-day Urticaria Activity Score (UAS7) of at least 16 and a weekly itch score of at least 8 after run-in are eligible for randomization.

The trial plans to randomize 124 participants in a 1:1 ratio using concealed block randomization through REDCap. Participants and outcome assessors are masked to allocation. The statistician will analyze coded groups. Clinicians performing the procedure know the assignment. Procedures are scheduled at baseline and week 2, with a 4-week treatment period and a further 4 weeks of follow-up. The primary analysis compares change from baseline in UAS7 at week 4. Other assessments include UAS7 at weeks 2 and 8, urticaria-related quality of life, serum total IgE, rescue medication use, adverse events, and symptom recurrence. Analyses are planned on an intention-to-treat basis.

Studietyp

Interventionell

Inskrivning (Beräknad)

124

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Sang Thanh Do, MD, MSc
  • Telefonnummer: +84 948 561 030
  • E-post: dtsang@ump.edu.vn

Studieorter

      • Ho Chi Minh City, Vietnam
        • Ho Chi Minh City Traditional Medicine Hospital, Outpatient Department
      • Ho Chi Minh City, Vietnam
        • Le Van Thinh Hospital, Department of Dermatology
      • Ho Chi Minh City, Vietnam
        • University Medical Center Ho Chi Minh City, Branch 3

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Age 18 years or older and willing to provide written informed consent.
  • Chronic urticaria diagnosed according to the EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline. Transient wheals and itching occur at least daily for more than 6 weeks despite prior or current use of an H1 antihistamine, without serious systemic symptoms. Individual wheals resolve within 30 minutes to 24 hours.
  • UAS7 of at least 16 and weekly itch score of at least 8 after the 7-day run-in.
  • No previous thread embedding acupuncture.

Exclusion Criteria:

  • Urticaria with an identified cause, including physical or mechanical urticaria.
  • Warning signs of systemic or autoinflammatory disease (e.g., Schnitzler syndrome or cryopyrin-associated periodic syndromes), or urticarial vasculitis.
  • Cutaneous mast cell disease or erythema multiforme.
  • Current or prior severe associated symptoms such as laryngeal edema, acute angioedema, anaphylaxis, or bradykinin-mediated angioedema including hereditary angioedema.
  • Other chronic pruritic skin disease that could interfere with assessment.
  • History of allergy to implant materials, especially absorbable suture or catgut, or a predisposition to keloid formation.
  • Current or recent immunosuppressive therapy or systemic corticosteroids within 2 to 4 weeks (or 30 days) before participation, as specified in the protocol.
  • Biologics such as omalizumab, leukotriene receptor antagonists, or H2 antihistamines within 7 to 14 days before screening or randomization, as specified in the protocol.
  • H1 antihistamine use above the recommended dose within 3 days before screening.
  • Psychotropic medication within the preceding month.
  • Malignancy or severe endocrine disorder.
  • Serious cardiovascular or cerebrovascular disease, diabetes mellitus, severe hepatic or renal failure, or a hematopoietic disorder.
  • Severe debilitation with reduced immune resistance.
  • Other serious systemic autoimmune disease, such as systemic lupus erythematosus.
  • Cognitive impairment, psychiatric illness, or a communication barrier that prevents participation in the treatment procedures.
  • A nonabsorbable implant at the intended procedure site.
  • Pregnancy, breastfeeding, or plans to become pregnant during the study.
  • Participation in another clinical trial in the preceding 3 months.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: PDO Thread Embedding Acupuncture Plus Cetirizine

Participants receive polydioxanone (PDO) thread embedding acupuncture at baseline and week 2, plus oral cetirizine as background treatment.

An absorbable monofilament polydioxanone (PDO) thread is implanted at seven bilateral acupuncture points (14 sites) at baseline and week 2.

Both arms receive cetirizine 10 mg orally each morning during the 7-day run-in and 4-week treatment period. Additional cetirizine use for rescue is recorded.

Sham Comparator: Sham Thread Embedding Acupuncture Plus Cetirizine

Participants receive a sham procedure at the same acupuncture points at baseline and week 2. The clinician uses an empty needle, so no thread is implanted. Participants also receive oral cetirizine as background treatment.

Both arms receive cetirizine 10 mg orally each morning during the 7-day run-in and 4-week treatment period. Additional cetirizine use for rescue is recorded.

The clinician inserts and withdraws an empty needle at the same acupuncture points at baseline and week 2. The procedure leaves no implanted thread.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change From Baseline in 7-Day Urticaria Activity Score (UAS7) at Week 4
Tidsram: Baseline and week 4

UAS7 is the sum of participant-reported daily hive and itch severity scores over seven consecutive days. The total ranges from 0 to 42, with higher scores indicating more severe symptoms. Change is calculated as the follow-up score minus baseline.

Baseline and week 4

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change From Baseline in UAS7 at Weeks 2 and 8
Tidsram: Baseline and weeks 2 and 8

UAS7 is the sum of participant-reported daily hive and itch severity scores over seven consecutive days. The total ranges from 0 to 42, with higher scores indicating more severe symptoms. Change is calculated as the follow-up score minus baseline.

Baseline and weeks 2 and 8
Change From Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) Score
Tidsram: Baseline and weeks 2, 4, and 8

Participants complete the disease-specific questionnaire about how chronic urticaria affected their lives in the preceding two weeks. Higher scores indicate greater impairment. Change is calculated as the follow-up score minus baseline.

Baseline and weeks 2, 4, and 8
Change From Baseline in Serum Total Immunoglobulin E (IgE)
Tidsram: Baseline and week 4

Serum total IgE is measured by enzyme-linked immunosorbent assay (ELISA) and reported in IU/mL. Change is calculated as the week 4 concentration minus baseline.

Baseline and week 4
Proportion of Participants With Adverse Events
Tidsram: From baseline through week 8

The study records adverse events and serious adverse events in each group during treatment and follow-up. Event severity is graded using the protocol-specified CTCAE criteria.

From baseline through week 8
Proportion of Participants Reporting Recurrence or Flare of Urticaria Symptoms
Tidsram: Weeks 4 through 8

Participants are contacted by telephone at week 8 using a standardized script to determine whether symptoms returned or flared during the post-treatment follow-up.

Weeks 4 through 8
Number of Rescue Cetirizine Tablets Used
Tidsram: From baseline through week 4

The total number of additional cetirizine tablets taken for symptom relief beyond the scheduled background dose is compared between groups.

From baseline through week 4

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Association of Baseline UAS7, Serum Total IgE, and Disease Duration With UAS7 at Week 4
Tidsram: Baseline and week 4

A multivariable linear regression will estimate the association of each baseline factor with week 4 UAS7, adjusting for study group and site.

Baseline and week 4

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Sang Thanh Do, MD, MSc, University of Medicine and Pharmacy at Ho Chi Minh City

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 juli 2027

Primärt slutförande (Beräknad)

1 februari 2029

Avslutad studie (Beräknad)

1 mars 2029

Studieregistreringsdatum

Först inskickad

12 november 2026

Först inskickad som uppfyllde QC-kriterierna

12 november 2026

Första postat (Faktisk)

18 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

12 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera